EXPLORATION OF CHEMICAL COMPOUNDS OF PODOPHYLLUM MEDICINAL PLANTS FOR BREAST CANCER THERAPY

Abstract

ABSTRACT EXPLORATION OF CHEMICAL COMPOUNDS OF PODOPHYLLUM MEDICINAL PLANTS FOR BREAST CANCER THERAPY In the present invention, six natural compounds derived from Podophyllum medicinal plants, namely 4-Demethylpodophyllotoxin (NP1), α-peltatin (NP2), podophyllotoxin (NP3), Deoxypodophyllotoxin (NP4), podophyllotoxone (NP5), and β-peltatin (NP6), were investigated as potential selective estrogen receptor α (ERα) inhibiting agents for breast cancer. These compounds demonstrated the strongest binding affinity to the target enzyme, with binding energies of -8.9 and -8.1 kcal/mol, respectively. Further assessments of drug-likeness and ADME properties were conducted for these compounds, along with quantum calculations highest occupied molecular orbital and lowest Unoccupied Molecular Orbital (HOMO-LUMO) to evaluate their reactivity. Additionally, molecular dynamics studies were performed to assess the stability of the NP1 and NP2 protein-ligand complexes.

Specification

Description:EXPLORATION OF CHEMICAL COMPOUNDS OF PODOPHYLLUM MEDICINAL PLANTS FOR BREAST CANCER THERAPY

FIELD OF THE INVENTION
The present invention relates to exploring compound suitability and employing DFT calculations, molecular docking, and dynamics simulation to investigate potent compounds from podophyllum medicinal plants for breast cancer therapy.
BACKGROUND
Breast cancer, one of the most often diagnosed malignancies worldwide, continues to take countless women's lives. Its treatment usually involves targeting the human estrogen receptor alpha (ERα). Breast cancer is a global health concern, impacting approximately 1.5 million individuals yearly. Among all types of cancers, it is the second leading cause of death among women. Projections indicate that by 2050, around 3.2 million women may receive a breast cancer diagnosis annually. In 2018, postmenopausal women were more likely to accept a breast cancer diagnosis than their premenopausal counterparts. In particular, 1.4 million postmenopausal women versus 645,000 premenopausal women received a breast cancer diagnosis. Additionally, it's critical to remember that postmenopausal women frequently experience higher breast cancer death rates. Women in more affluent countries tend to experience a higher incidence of new cases for a specific condition. In contrast, women in less economically developed nations face a greater risk of mortality associated with the same circumstance. One of the primary factors contributing to the development of breast cancer is the overproduction of estrogen. According to a report, the 17β-estradiol molecule, also known as estrogen, effectively activates the nuclear receptor. ER-alpha (ER-α) and ER-beta (ER-β) estrogen receptors are naturally present in the human population. Still, ER-α is more commonly expressed in the uterus and mammary glands. The estrogen receptor significantly influences various aspects of breast cancer, including apoptosis, inflammation, homeostasis, differentiation, metabolism, maturation, and proliferation in women.
The receptor ERα is widely recognized for its involvement in immune surveillance, its role in resisting apoptosis, its contribution to metastasis, and its influence on cell growth. The increased action of the estrogen hormone may cause the ER-alpha to multiply in mammalian cells, contributing to the maintenance and development of different types of breast cancers. It also contains several attractive molecular targets for the development of cancer drugs. The ERα receptor shows how virtual screening (VS) might be a practical method to find and screen potential compounds from various natural sources. Several VS methods, molecular docking, general pharmacophore hypothesis, and molecular dynamic simulations must discover ER receptor ligands.
Utilizing plants for medicinal purposes traces its roots back to ancient civilizations. Over time, plants have consistently proven to be a dependable source of anti-cancer remedies.
Podophyllotoxin is derived from the dried roots and rhizomes of either Podophyllum emodi or Podophyllum hexandrum, which belong to the Berberidaceae family. The origins and rhizome of Podophyllum peltatum serve as the primary sources for American Podophyllum. The resin content, known as podophyllin, in Indian Podophyllum typically ranges from 7% to 15%. The resin content within Podophyllum can vary based on factors such as the collection season, geographical region, and the specific part of the plant harvested, whether the essential lignan derivatives discovered in podophyllum resin are podophyllotoxin, -peltatin, and -peltatin. Both free aglycones and glycosides of these lignans are present in the resin. Other elements of podophyllum resin include desmethyl podophyllotoxin, desoxypodophyllotoxin, podophyllotoxone, the flavonoid quercetin, and starch.
Podophyllotoxin is used to treat several medical conditions, including both venereal and non-venereal warts. A powerful anti-cancer medication called etoposide is made from this organic compound. Etoposide is frequently administered to treat lung and testicular cancer. Derivatives of podophyllotoxin also exhibit various pharmacological characteristics, such as their efficacy as antimitotic medicines, rheumatoid arthritis therapies, and antiviral drugs.
However, cycloligands' potential to have anti-cancer effects has shown much promise. Numerous research teams worldwide are actively modifying the podophyllotoxin scaffold's structure to increase its efficiency in treating cancer.
Previous studies have evaluated the potential of 2-anilinopyrimidine compounds as treatments for triple-negative breast cancer through computational pharmacokinetic analysis and quinazoline derivatives, arylamides derived from flavones, and analogs of chromen-2-ones as anti-cancer medications. Integral to these investigations are assessments of drug-likeness, computer modeling, ligand-based drug design, and research into ADMET properties. Computational prediction models are critical in guiding the methodology selection process for pharmaceutical and technology research. Molecular docking, drug-likeness, and ADMET properties primarily help in advanced drug testing. Enhanced and potent derivative chemicals were developed through the utilization of the QSAR mathematical model for parthenolide derivatives in breast cancer treatment.
Computer-aided approaches to drug discovery have evolved as improved technologies that help to screen for medications derived from phytochemicals in various medicinal plants. Certain natural compounds from V. vinifera, Hibiscus sabdariffa, eugenol compounds, and Cichorium intybus may be valuable in the search for molecules targeting breast cancer.
Considering the above facts, the previous study explored the chemical constituents and evaluated the in vitro bioactivity of Podophyllum compounds extract. At present, this invention aims to indicate the drug candidate from Podophyllum medicinal plants that can act as a selective estrogen receptor α (ERα) inhibiting agent for Breast cancer. We initiated the virtual screening of compounds, quantum calculations (HOMO-LUMO), molecular docking, and molecular dynamics to single out new drug candidates that target breast cancer.
The present invention utilized a comprehensive approach to identify promising natural compounds for breast cancer treatment, including quantum descriptors, molecular docking, molecular dynamics simulations (MD), and absorption, distribution, metabolism, excretion, (ADME)/pharmacokinetics analysis. It explores the potential of natural compounds to regulate ERα activity, providing a hopeful direction for breast cancer therapy.
SUMMARY OF THE INVENTION
The present invention relates to exploring compound suitability and employing DFT calculations, molecular docking, and dynamics simulation to investigate potent compounds from podophyllum medicinal plants for breast cancer therapy.
According to an embodiment of the present invention, between six natural compounds derived from the Podophyllum plant, namely 4-Demethylpodophyllotoxin (NP1), α-peltatin (NP2), podophyllotoxin (NP3), Deoxypodophyllotoxin (NP4), podophyllotoxone (NP5), and β-peltatin (NP6), were evaluated. We employed drug-likeness and ADME (Absorption, Distribution, Metabolism, and Excretion) analyses, along with DFT (Density Functional Theory) calculations, followed by molecular dynamics (MD) simulations to investigate their potential as drug candidates. One of the key factors influencing the binding affinity of natural compounds is their adherence to Lipinski's Rule of Five (RO5), a set of criteria used to predict a molecule's oral bioavailability. In our study, the natural compounds displayed favorable properties as their molecular weights were below 500, partition coefficients were less than 5, and the number of hydrogen bond donors and acceptors fell within the recommended limits of ≤ 5 and ≤ 10, respectively. These findings indicate that these compounds hold promise for oral bioavailability, a critical aspect of drug development, as shown in Table 2. Additionally, we conducted in-silico ADMET screening to assess the pharmacokinetic and toxicity profiles of the designed compounds (Table 3). Encouragingly, most of the compounds met the recommended values for essential ADMET parameters, suggesting their potential as viable drug candidates.
According to another embodiment of the present invention, primary focus is on the molecular and pharmacokinetic aspects and it's essential to recognize the broader context of drug development. Quantum computing has emerged as a promising tool for enhancing drug discovery processes, but several challenges need addressing before its widespread adoption. Nevertheless, quantum computing is poised to play a significant role in this field. Intriguingly, we also explored the structural optimization of Podophyllum compounds using density functional theory with B3LYP/6-31g (d,p) level theory. We observed their optimized structures and dipole moments and examined HOMO-LUMO energies, energy gap, Ionization potential, Electronegativity, hardness, softness, and chemical potential. These insights contribute to understanding the chemical properties of these compounds.
According to another embodiment of the present invention, the important objective was to achieve insights into the binding approaches of the six natural compounds (NP1, NP2, NP3, NP4, NP5, and NP6) within the active site of the human estrogen receptor alpha (ER alpha), assessing their potential as inhibitors. Our docking studies employed the crystal structure of ER alpha (PDB: ID: 3ERT), a known drug target for inhibitory activity. The interactions revealed through docking simulations are instrumental in understanding the significant affinity of these natural compounds toward the human estrogen receptor. The Autodock vina binding affinity results (Table 5) quantitatively measure binding affinity.
According to another embodiment of the present invention, molecular dynamics simulations for NP1 and NP2 with the target protein complex was conducted, demonstrating the stability of the protein-ligand interactions. These simulations provide valuable insights into the dynamic behavior of the complexes.
According to another embodiment of the present invention, these compounds exhibit favorable properties regarding Lipinski's Rule of Five compliance, promising ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) profiles, and strong binding affinity to the hER alpha receptor. These characteristics make them well-suited for further exploration in drug development efforts.
Moreover, computational analyses have provided valuable insights into these compounds' structural optimization and energetic aspects, enhancing the understanding of their pharmacological potential. We plan to conduct molecular dynamics simulation studies to validate our findings and assess the stability of compounds NP1 and NP2 in complex interactions with proteins. These simulations will contribute to the comprehensive evaluation of these compounds therapeutic potential as potential inhibitors. Such inhibitors could hold significant promise in treating diseases, particularly those associated with breast cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows chemical structure of podophyllotoxin dervivatives (NP1-NP6).
Figure 2 shows optimized chemical structure, free energy (in Hartree), and dipole moment (Debye) of all compounds.
Figure 3 shows HOMO-LUMO and energy gap of NP1 and NP2.
Figure 4 shows NP1 with a protein complex and their mutual interactions.
Figure 5 shows NP2 with a protein complex and their mutual interactions.
Figure 6 shows MD Simulation Analysis of Protein Complexes with NP1 and NP2.
DETAILED DESCRIPTION OF THE INVENTION
The following description includes the preferred best mode of one embodiment of the present invention. Reference now will be made in detail to embodiments of the invention, one or more examples of which are illustrated in the drawings. Each example is provided by way of explanation of the invention, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention.
Methods
Protein preparation
The crystallographic structure of ER α, a significant protein target linked to breast cancer, has been successfully determined to have a high resolution of 1.90. A detailed analysis of the precise three-dimensional structure of the ER α in conjunction with an inhibitor has also been performed, and it is currently accessible in the Protein Data Bank (PDB), under the PDB code 3ERT. The crystal structure of the water molecules was initially missing, leaving valencies that needed to be filled up with hydrogen atoms. Before conducting more research, the chemical structure was optimized using the minimized structure feature of the UCSF Chimaera version 1.12. The molecule was further enhanced using the AutoDock program by adjusting charges and including polar hydrogen atoms. The protein structure was then produced into a protein data pank, partial charge, & atom type format (PDBQT) file for future research.
Ligand preparation
The collection of six naturally occurring compounds specific to various species of Podophyllum was collected from existing literature. The 3D structures of these molecules were obtained from the PubChem database and shown in Table 1. The molecular scaffold for podophyllotoxin is presented in Figure 1. All the molecules underwent energy minimization/optimization, following which the Autodock tool was used to generate input files in PDQT format for subsequent molecular docking studies.
Table 1: List of natural compounds and their associated functional groups.
S.NO Name of natural compounds PubChem (CID) R1 R2 R3
NP1 4-Demethylpodophyllotoxin 122667 OH H OH
NP2 α-peltatin 92129 H OH OH
NP3 Podophyllotoxin 10607 OH H OCH3
NP4 Deoxypodophyllotoxin 345501 H H OCH3
NP5 Podophyllotoxone 443014 =O H OCH3
NP6 β-peltatin 92122 H OH OCH3

Drug-likeness and ADME properties
Lipinski's Rule of Five (RO5) criteria for physicochemical properties define an ideal therapeutic molecule. According to Lipinski's Rule of Five is a method for predicting the drug-like properties of a chemical molecule intended for oral delivery. According to RO5, a chemical must have a molecular weight (MW) below a predetermined threshold, usually around 500 daltons, have no more than five hydrogen bond donors (HBDs), and have no more than ten hydrogen bond acceptor (HBA) sites to classified as drug-like. These recommendations are crucial in the initial phases of drug discovery and aid in identifying substances with a better chance of success in developing oral drugs.
The pharmacokinetic properties of ligand molecules are described through absorption, distribution, metabolism, and excretion (ADME). These parameters hold significant importance in uncovering and advancing novel drug candidates. The Swiss ADME server measures the ADME characteristics of the docked compounds. It is a free online tool to forecast tiny compounds' drug-like properties.
DFT Calculations
Gaussian 09 software was used to compute the theoretical modelling for the molecule's ground state. The Gaussian View 5 program is used to depict the molecular structure of the optimized molecule. The natural chemical molecule was theoretically calculated using B3LYP and 6-311G (d,p). We comprehensively analyzed each molecule, including determining its internal electronic energy, enthalpy, Gibbs free energy, and dipole moment. Additionally, we performed Frontier Molecular Orbital (FMO) calculations using the same level of theory. To further characterize the chemical properties of the drugs. We determined the hardness (η) and softness (S) of the system by evaluating the energies associated with the Highest Occupied Molecular Orbital HOMO) and the Lowest Unoccupied Molecular Orbital (LUMO), employing the framework and methodology established by Parr and Pearson within the realm of Density Functional Theory (DFT). Our calculations also considered Koopmans' theorem, which correlates ionization potential (I) and electron affinities (E) with HOMO and LUMO energy (𝜀), hardness (η), and softness (S).
IP=-E_HOMO EA=-E_LUMO μ=(E_HOMO+E_LUMO)/2 η=(E_HOMO-E_LUMO)/2 Molecular docking
We utilized the AutoDock Tools (ADT) graphical user interface program to facilitate several crucial intermediate steps in our molecular docking investigation. These steps encompassed the preparation of both protein and ligand structures and the creation of a docking grid. Our utilization of ADT began with several vital tasks. It assigned polar hydrogens to the protein, given united atom Kollman charges, specified solvation parameters, and determined fragmental volumes. The resulting prepared file was then saved in the PDBQT format for compatibility with further steps. Following this, we employed AutoGrid to generate a grid map necessary for our docking experiment. The grid size was configured to 32× 24 × 32 xyz points, with a grid spacing of 0.375 Å. The coordinates (x, y, and z) defined the grid center: 29.899, -1.887, and 24.492. A scoring grid was computed based on the ligand structure to optimize computational efficiency. We employed AutoDock/Vina, which utilizes an iterated local search global optimizer for the actual docking process. In this procedure, both the protein and ligands were considered rigid entities. Subsequently, we grouped results with a positional root-mean-square deviation (RMSD) of less than 3.0 Å to form clusters. The representative result was chosen based on the most favorable binding affinity. To conclude, we extracted the binding pose with the lowest energy or the highest binding affinity and aligned it with the receptor structure for further in-depth analysis. The interface between receptors and ligands was analyzed using Discovery Studio Visualizer.
Molecular Dynamics Simulation
After conducting docking studies, the lead compounds derived from the Podophyllum plant were further investigated through molecular dynamics (MD) simulation studies. These simulations aimed to assess the binding efficacy of the lead compounds and elucidate their impact on the internal dynamics of the target protein. The MD simulations for this study were carried out using the GROMACS-2018.1 biomolecular software package, which is well-regarded for its accuracy in computing non-bonded interactions. It is a pivotal tool for research in simulation studies. We generated ligand topologies using the CGENFF method to set up the simulations. We employed the CHARMM36 force field for ligands and proteins to determine their topologies. The simulation protocol began with an initial phase of energy minimization in a vacuum, utilizing the steepest descent method. During this process, a distance of 10 units is maintained between each protein complex and the edges of the simulation box. We introduced solvent molecules using the TIP3P water model to mimic the physiological environment.
Additionally, to achieve a salt concentration of 0.15 M, we added Na+ and Cl− ions appropriately. The MD simulations were run for 100 nanoseconds while maintaining a 310 Kelvin temperature and a 1 bar pressure. We then conducted trajectory analysis to evaluate the structural changes during the simulation, mainly concentrating on the root-mean-square deviation (RMSD). The results were then visualized and presented graphically using the XMGRACE software.
Results
The primary objective of this invention is to assess the drug-like properties of six natural compounds, namely NP1, NP2, NP3, NP4, NP5, and NP6. This assessment aims to characterize the biological activity of these compounds and explore their potential beneficial or toxic effects if they were to be utilized in pharmaceutical applications. The evaluation results, presented in Table 2, indicate that these compounds conform to Lipinski's rules. This conformity suggests that there are no significant concerns regarding their oral bioavailability. Furthermore, these compounds exhibit a high absorption capacity, resulting in an increased metabolic turnover, excellent solubility, and enhanced oral absorption. Specifically, their molecular weight falls within the range of 398.41 to 414.41 g/mol, under the widely accepted threshold of 500 g/mol. Additionally, the number of hydrogen bond acceptors (HBA) ranges from 7 to 8, a value that does not exceed the mentioned limit 10. The count of hydrogen bond donors (HBD) falls from 0 to 2, well below the maximum threshold of 5. The total surface area is 72.45 to 103.66 Å2, less than the typical cutoff of 140 Å2. Lastly, the number of rotatable bonds is fewer than 10. In conclusion, based on the adherence to Lipinski's rules and the favorable drug-like properties exhibited by these compounds, it is reasonable to consider them as potential candidates for further exploration in pharmaceutical applications. The details of these compounds can be found in Table 2.
Table 2: Exploring Linpinskri's natural compound rule
S.NO MW (g/mol) HBA HBD XLogP3 TPSA (Å) RB
NP1 400.38 8 2 1.68 103.68 3
NP2 400.38 8 2 2.60 103.68 3
NP3 414.41 8 1 2.01 92.68 4
NP4 412.39 8 0 2.51 89.52 4
NP5 398.41 7 0 3.12 72.45 4
NP6 414.41 8 1 2.93 92.66 4
When utilizing Swiss ADME calculations, it has been determined that all tested drugs exhibit high solubility within the gastrointestinal (GI) environment. Additionally, Table 3 indicates that there is no evidence that these drugs match the criteria necessary for passage through the blood-brain barrier (BBB), suggesting that they cannot reach the central nervous system. Notably, these drugs have been identified as non-inhibitors of P-glycoprotein, a significant finding that enhances their potential for absorption, permeability, and retention within the body. Swiss ADME analysis extends its utility by offering valuable insights into the potential interactions of these drugs with cytochrome enzymes, with a particular focus on the CYP450 family. These enzymes are essential in drug metabolism, making them crucial pharmacology and drug development factors. Understanding how a drug may impact or be influenced by these critical enzymes is vital to making informed decisions during the drug development process, as presented in Table 3.
Table 3: ADME properties of Natural compounds
S.NO GI abs BBB P-gp CYP
1A2 CYP
2C19 CYP
2C9 CYP
2D6 CYP
3A4 Log Kp
NP1 High No No No No No Yes No -7.55
NP2 High No No No No Yes Yes Yes -6.90
NP3 High No No No No No Yes Yes -7.40
NP4 High No No No No Yes Yes Yes -7.03
NP5 High Yes No No Yes Yes Yes Yes -6.52
NP6 High No No No No Yes Yes Yes -6.75

This study has revealed the optimized energy levels of various natural compounds, including NP1 at -1414.3 Hartree, NP2 at -1414.3 Hartree, NP3 at -1453.6 Hartree, NP4 at -1452.4 Hartree, NP5 at -1378.4 Hartree, and NP6 at -1453.6 Hartree. Additionally, the investigation also documented the dipole moments of these natural compounds, with NP1 displaying a dipole moment of 1.2 Debye, NP2 at 2.8 Debye, NP3 at 3.2 Debye, NP4 at 4.8 Debye, NP5 at 6.1 Debye, and NP6 at 7.1 Debye, as summarized in Figure 2.
We have chosen NP1 and NP2 for further investigation, and their HOMO-LUMO gaps are -5.11 eV and 5.40 eV, respectively, as depicted in Figure 3. Table 4 displays the chemical potential values for NP1 (-32 eV) and NP2 (-2.9 eV), along with their corresponding chemical softness values (0.39 and 0.37). These data suggest that both NP1 and NP2 exhibit characteristics indicative of higher chemical reactivity.
Table 4: HOMO, LUMO, IP, EA, gap, hardness, softness, and chemical potential of NP1 and NP2 compounds.
S.No HUMO(eV) LUMO (eV) IP EA Energy Gap Hardness Softness Chemical potential

NP1 -5.76 -0.64 5.76 0.64 5.11 2.55 0.39 -3.2
NP2 -5.63 -0.23 563 0.23 5.40 2.70 0.37 -2.9

Table 5 displays the findings from molecular docking investigations, highlighting the binding energies (measured in kcal/mol) for a range of compounds. To elaborate, NP1 displayed a binding affinity of -8.9 kcal/mol, NP2 demonstrated -8.6 kcal/mol, NP3 exhibited -8.5 kcal/mol, NP4 showed -8.5 kcal/mol, while both NP5 and NP6 showcased comparable binding energies of -8.1 kcal/mol.
Table 5: The binding affinity and the bond interactions of all compounds
S.NO Binding affinity (Kcal/mol) Hydrogen bond interactions Pi-bond and Carbon hydrogen bond interactions
NP1 -8.9 VAL A: 534, LEU A:536 ASP A: 351, LEU A:354, MET A: 522, LEU A: 525, VAL A: 533
NP2 -8.6 LEU A: 536 ASP A: 351, LEU A:354,
MET A: 522, LEU A: 525, VAL A: 533, LEU A: 536
NP3 -8.5 LEU A: 536 ASP A: 351, LEU A:354,
MET A: 522, LEU A: 525, VAL A: 533, LEU A: 536
NP4 -8.5 LYS A: 531 ASP A: 351, MET A: 522, LEU A: 525, LYS A: 529, LEU A: 536
NP5 -8.1 LEU A: 536 MET A: 522, LEU A: 354, TRP A: 383
NP6 -8.1 LYS A: 531 ASP A: 351, TRP A:383,
MET A: 522, LEU A: 525, LEU A: 536

The compound NP1 demonstrates a high binding affinity, measuring at -8.9 kcal/mol, and it establishes several crucial connections with the target protein. These connections encompass hydrogen bonds formed with VAL A:534 and LEU A:536 residues, a Pi-Alkyl interaction with LEU A:354, as well as Pi-Sigma and Pi-Sulfur interactions with MET A:522. Furthermore, there is a notable carbon-hydrogen bond interaction between ASP A:351 and LEU A:525, in addition to two distinct interactions involving VAL 533 and LEU A:536, as shown in Figure 4.
NP2 exhibits a strong binding affinity of -8.6 kcal/mol. This binding is characterized by multiple interactions, including three hydrogen bond interactions involving LEU A:536 and Pi-Alkyl interactions with LEU A:354, MET A:522, and VAL 533. Furthermore, LEU A:536 is engaged in three distinct interactions. At the same time, LEU A:539 participates in carbon-hydrogen bonding with ASP A:351, and LEU A:525 engages in a Pi-Sulfur interaction with MET A:522, as shown in Figure 5.
To gain deeper insights into the dynamic interactions between ligands and receptors and elucidate the binding modes of small molecules, we conducted molecular dynamics simulations lasting 100 nanoseconds for compounds NP1 and NP2 based on their docking results. The RMSD (Root Mean Square Deviation) plot, as depicted in Figure 6, exhibited consistent patterns. Both complexes displayed minimal RMSD fluctuations, ranging between 0.18 ± 0.4 nm and 0.18 ± 0.38 nm. This constant and low variability in RMSD values suggests a highly stable and confined binding arrangement for NP1 and NP2 within the binding site of the target protein.
, Claims:I/WE CLAIM
1. A method of exploration of chemical compounds of podophyllum medicinal plants comprises the steps of:
a) performing detailed analysis of the precise three-dimensional structure of the ER α in conjunction with an inhibitor;
b) collecting the six naturally occurring compounds specific to various species of Podophyllum; and
c) carrying out pharmacokinetic analysis, along with Molecular docking, DFT (Density Functional Theory) calculations, followed by molecular dynamics (MD) simulations to investigate their potential as drug candidates.
2. The method as claimed in claim 1, wherein the six naturally occurring compounds exhibit a high absorption capacity, resulting in an increased metabolic turnover, excellent solubility, and enhanced oral absorption.
3. The method as claimed in claim 1, wherein the molecular weight of the compounds falls within the range of 398.41 to 414.41 g/mol, under the widely accepted threshold of 500 g/mol.
4. The method as claimed in claim 1, wherein the said compounds have been identified as non-inhibitors of P-glycoprotein, a significant finding that enhances their potential for absorption, permeability, and retention within the body.
5. The method as claimed in claim 1, wherein the docking studies show the significant affinity of these natural compounds towards the human estrogen receptor.
6. The method as claimed in claim 1, wherein dynamics simulations for NP1 and NP2 with the target protein complex, demonstrates the stability of the protein-ligand interactions.
7. The method as claimed in claim 1, wherein the compounds derived from Podophyllum medicinal plants, namely 4-Demethylpodophyllotoxin (NP1), α-peltatin (NP2), podophyllotoxin (NP3), Deoxypodophyllotoxin (NP4), podophyllotoxone (NP5), and β-peltatin (NP6) demonstrated the strongest binding affinity to the target enzyme, with binding energies of -8.9 and -8.1 kcal/mol, respectively.

Documents